Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating
瑞穗將Cerevel Therapeutics的目標股價從25美元上調至45美元，以反映對艾伯維的銷售價格，維持中性評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！